As of his appointment at Allogene Therapeutics, Geoffrey Parker holds impressive options and restricted stock units that highlight his commitment to the company. In 2023 alone, he received stock options to purchase approximately 950,000 shares, aligning his interests with those...

As of his appointment at Allogene Therapeutics, Geoffrey Parker holds impressive options and restricted stock units that highlight his commitment to the company. In 2023 alone, he received stock options to purchase approximately 950,000 shares, aligning his interests with those of shareholders. Moreover, he has 400,000 shares in restricted stock units, vesting over four years, which suggests that he has skin in the game. His total 2023 compensation amounted to about $1.47 million, which includes a combination of salary, bonus, and vested stock. With such a significant amount linked to Allogene's stock performance, it shows that Geoffrey is well positioned to share in the company's future successes, especially as it works towards regulatory approvals for its therapies. His holdings reflect not just a personal wealth interest but also a shared destiny with the company.